Ken Fisher’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Ken Fisher’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-23,864	Closed	-$1.06M	–	993
2022 Q2	$1.06M	Buy	23,864 +9,800	+70%	+$450K	﹤0.01%	623
2022 Q1	$696K	Buy	14,064 +4,507	+47%	+$216K	﹤0.01%	672
2021 Q4	$487K	Hold	9,557	–	–	﹤0.01%	765
2021 Q3	$533K	Hold	9,557	–	–	﹤0.01%	722
2021 Q2	$409K	Buy	9,557 +2,884	+43%	+$119K	﹤0.01%	750
2021 Q1	$279K	Sell	6,673 -2,332	-26%	-$108K	﹤0.01%	803
2020 Q4	$419K	Sell	9,005 -31	-0.3%	-$1.45K	﹤0.01%	737
2020 Q3	$384K	Sell	9,036 -5,300	-37%	-$232K	﹤0.01%	700
2020 Q2	$688K	Hold	14,336	–	–	﹤0.01%	619
2020 Q1	$659K	Hold	14,336	–	–	﹤0.01%	588
2019 Q4	$861K	Sell	14,336 -3,507	-20%	-$209K	﹤0.01%	600
2019 Q3	$1.01M	Hold	17,843	–	–	﹤0.01%	610
2019 Q2	$993K	Sell	17,843 -91	-0.5%	-$4.75K	﹤0.01%	604
2019 Q1	$905K	Buy	17,934 +9	+0.1%	+$400	﹤0.01%	591
2018 Q4	$722K	Hold	17,925	–	–	﹤0.01%	621
2018 Q3	$1.24M	Sell	17,925 -2,827	-14%	-$214K	﹤0.01%	570
2018 Q2	$1.57M	Sell	20,752 -9,032	-30%	-$568K	﹤0.01%	548
2018 Q1	$1.57M	Hold	29,784	–	–	﹤0.01%	538
2017 Q4	$1.59M	Buy	29,784 +5,863	+25%	+$326K	﹤0.01%	544
2017 Q3	$1.43M	Buy	23,921 +12,876	+117%	+$779K	﹤0.01%	531
2017 Q2	$871K	Buy	11,045 +3,365	+44%	+$275K	﹤0.01%	550
2017 Q1	$637K	Buy	7,680 +1,900	+33%	+$141K	﹤0.01%	544
2016 Q4	$459K	Sell	5,780 -3,770	-39%	-$274K	﹤0.01%	571
2016 Q3	$669K	Sell	9,550 -2,911	-23%	-$161K	﹤0.01%	543
2016 Q2	$555K	Hold	12,461	–	–	﹤0.01%	550
2016 Q1	$464K	Hold	12,461	–	–	﹤0.01%	571
2015 Q4	$1.1M	Hold	12,461	–	–	﹤0.01%	503
2015 Q3	$922K	Buy	+12,461	New	+$1.04M	﹤0.01%	500

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ken Fisher's EGRX Position: Q3 2022 in Review

Ken Fisher sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 23,864 shares — an estimated $1.06M sold.

Ken Fisher first reported a position in EGRX in Q3 2015 and held it in 28 quarters. The position peaked at $1.59M in Q4 2017. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

Ken Fisher reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Ken Fisher sold 23,864 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $1.06M.
Ken Fisher first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 28 quarters.
Ken Fisher's Eagle Pharmaceuticals, Inc. position peaked at $1.59M in Q4 2017.
153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Fisher Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.